Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Phase 2 Completed N=39 Randomized Triple-blind Treatment

Fish Oil for the Treatment of Depression in Patients With Multiple Sclerosis

Multiple Sclerosis · Depression
Source: ClinicalTrials.gov NCT00122954 ↗
Enrolled (actual)
39
Serious AEs
0.0%
Results posted
Jan 2014
Primary outcomePrimary: Montgomery-Asberg Depression Rating Scale (MADRS) — 45.5; 47.4 percentage of subjects

Summary

This study will determine whether fish oil can reduce depression in people with multiple sclerosis (MS) who are mild to moderately depressed and are currently taking antidepressant medication. Study hypothesis: Three months of fish oil supplementation will improve depression scores on the Montgomery-Asberg depression rating scale (MADRS) or Beck Depression Inventory (BDI) better than placebo.

Outcome Measures

OutcomeResultp-value
PRIMARY
Montgomery-Asberg Depression Rating Scale (MADRS)		 45.5; 47.4 —
SECONDARY
Quality of Life (SF-36)		 -0.8; 1.6; 4.2; 1.5 —

Eligibility Criteria

Inclusion Criteria

  • Diagnosis of relapsing-remitting MS
  • Diagnosis of depressive disorder
  • Score between 11 and 30 on the Montgomery-Asberg Depression Rating Scale (MADRS)
  • Score of 25 or greater on the Mini-Mental State Examination (MMSE)
  • Currently taking antidepressant medication for at least 3 months prior to study entry

Exclusion Criteria

  • Currently taking fatty acid supplements
  • Consume more than 6 oz of fish per week within 1 month prior to study entry
  • Severe depression
  • Suicidal thoughts
  • Other psychological disorders
  • Currently taking more than two types of antidepressants
  • Any serious medical condition that would interfere with the study
  • Worsening of MS symptoms or corticosteroid treatment within 1 month prior to study entry
  • Current enrollment in another fish oil study
  • Pregnancy
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00122954). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search